Dextera Surgical Inc (NASDAQ:DXTR) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Zacks Investment Research has downgraded Dextera Surgical Inc (NASDAQ:DXTR) to Sell in a statement released on 10/11/2016.
Boasting a price of $1.98, Dextera Surgical Inc (NASDAQ:DXTR) traded -4.74% lower on the day. With the last stock price close down -24.01% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Dextera Surgical Inc has recorded a 50-day average of $1.92 and a two hundred day average of $2.48. Volume of trade was down over the average, with 6,673 shares of DXTR changing hands under the typical 14,282
With a total market value of $0, Dextera Surgical Inc has with a one year low of $1.10 and a one year high of $4.30 .
More About Dextera Surgical Inc (NASDAQ:DXTR)
Dextera Surgical Inc, formerly Cardica, Inc., is focused on the commercialization and development of microcutter product line intended for use by surgeons. The Company is engaged in commercializing and developing MicroCutter XCHANGE 30 based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter XCHANGE 30 is a cartridge based microcutter device with around five millimeter shaft diameter and around 30 millimeter staple line cleared for use in the United States for specific indications for use, and in the European Union for a range of indications for use. Its planned products include MicroCutter XCHANGE 45, MicroCutter XCHANGE 60 and MicroCutter FLEXCHANGE 30. The MicroCutter FLEXCHANGE name refers to the planned cartridge-based microcutter product with a flexible shaft that also includes its staple-on-a-strip technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.